Future studies based on a comparison between the accuracy of the cytokine and cell-expression markers assessed in this study with other more specific immune biomarkers recently used for diagnosis and staging of MASLD (such as TIM4, TREM2, VSIG4, and FOLR2, all commonly associated with Kupffer cells) could further clarify immunomodulatory processes undergone during MASLD progression. This evidence concerns the gene TIMD4 and metabolic dysfunction-associated steatotic liver disease.